Lunit Inc. (KOSDAQ:328130)

South Korea flag South Korea · Delayed Price · Currency is KRW
62,900
+300 (0.48%)
Feb 21, 2025, 3:30 PM KST
-4.70%
Market Cap 1.82T
Revenue (ttm) 39.54B
Net Income (ttm) -21.97B
Shares Out 29.00M
EPS (ttm) -2,052.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 415,880
Average Volume 1,479,602
Open 62,600
Previous Close 62,600
Day's Range 62,600 - 64,800
52-Week Range 31,000 - 85,800
Beta 1.46
RSI 43.80
Earnings Date Feb 14, 2025

About Lunit

Lunit Inc. provides AI-powered software and solutions for cancer diagnostics and therapeutics in South Korea. It offers AI solution for chest X-ray and mammography, as well as AI solution for digital breast tomosynthesis, and AI-powered biomarker for immune phenotyping and PD-L1 biomarker analyzer. The company has a strategic collaboration with AstraZeneca for the development of Lunit SCOPE Genotype Predictor, an AI-powered tool capable of analyzing H&E slide images to predict the likelihood of the tumor harboring NSCLC driver mutations, such a... [Read more]

Industry Prepackaged Software
Founded 2013
Employees 345
Stock Exchange KOSDAQ
Ticker Symbol 328130
Full Company Profile

Financial Performance

In 2023, Lunit's revenue was 25.08 billion, an increase of 80.88% compared to the previous year's 13.87 billion. Losses were -36.80 billion, -5.93% less than in 2022.

Financial Statements

News

There is no news available yet.